Related Experiment Video
Updated: Jun 24, 2026
07:48
An Orthotopic Bladder Cancer Model for Gene Delivery Studies
Published on: December 1, 2013
Targeting angiogenesis in bladder cancer
Aymen A Elfiky1, Jonathan E Rosenberg
1Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, 44 Binney Street, D1230, Boston, MA 02115, USA.
Current Oncology Reports
|April 2, 2009
Summary
Metastatic bladder cancer is a leading cause of death. Antiangiogenic therapies targeting vascular endothelial growth factor are showing promise in treating advanced bladder cancer and improving patient survival.
Area of Science:
- Oncology
- Cancer Biology
- Medical Research
Background:
- Metastatic disease is the primary cause of mortality in bladder cancer patients.
- Understanding the interconnected mechanisms of invasion, metastasis, and angiogenesis is crucial for developing effective treatments.
- Vascular endothelial growth factor (VEGF) levels are a significant prognostic indicator in advanced bladder cancer.
Purpose of the Study:
- To review key developments in antiangiogenic therapy for bladder cancer.
- To highlight the role of angiogenesis inhibition in treating advanced bladder cancer.
- To discuss the potential of antiangiogenic agents in improving patient survival.
Main Methods:
- Review of preclinical and clinical studies on antiangiogenic agents in bladder cancer.
- Analysis of the prognostic significance of vascular endothelial growth factor (VEGF) in advanced bladder cancer.
- Evaluation of the anticancer activity of angiogenesis inhibitors.
Main Results:
- Preclinical studies demonstrate anticancer activity of angiogenesis inhibition.
- Vascular endothelial growth factor (VEGF) levels correlate with patient outcomes in advanced bladder cancer.
- Several antiangiogenic agents (sunitinib, sorafenib, bevacizumab) are under investigation for advanced bladder cancer.
Conclusions:
- Antiangiogenic therapy represents a promising strategy for advanced bladder cancer.
- Targeting angiogenesis may improve survival rates for patients with metastatic bladder cancer.
- Continued research into antiangiogenic agents is essential for advancing bladder cancer treatment.
Related Concept Videos
01:10Mechanism of Angiogenesis
Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:24Regulation of Angiogenesis and Blood Supply
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...